These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30144428)

  • 1. TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes.
    Boyer A; Park SB; de Boer YS; Li Q; Liang TJ
    Gastroenterology; 2018 Dec; 155(6):1923-1935.e8. PubMed ID: 30144428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C Virus Lipoviroparticles Assemble in the Endoplasmic Reticulum (ER) and Bud off from the ER to the Golgi Compartment in COPII Vesicles.
    Syed GH; Khan M; Yang S; Siddiqui A
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28515296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neglected but Important Role of Apolipoprotein E Exchange in Hepatitis C Virus Infection.
    Yang Z; Wang X; Chi X; Zhao F; Guo J; Ma P; Zhong J; Niu J; Pan X; Long G
    J Virol; 2016 Nov; 90(21):9632-9643. PubMed ID: 27535051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III.
    Sun HY; Lin CC; Lee JC; Wang SW; Cheng PN; Wu IC; Chang TT; Lai MD; Shieh DB; Young KC
    Gut; 2013 Aug; 62(8):1193-203. PubMed ID: 22689516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells.
    Jammart B; Michelet M; Pécheur EI; Parent R; Bartosch B; Zoulim F; Durantel D
    J Virol; 2013 May; 87(9):5065-80. PubMed ID: 23427158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A serum protein factor mediates maturation and apoB-association of HCV particles in the extracellular milieu.
    Denolly S; Granier C; Fontaine N; Pozzetto B; Bourlet T; Guérin M; Cosset FL
    J Hepatol; 2019 Apr; 70(4):626-638. PubMed ID: 30553840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection.
    Sheridan DA; Hajarizadeh B; Fenwick FI; Matthews GV; Applegate T; Douglas M; Neely D; Askew B; Dore GJ; Lloyd AR; George J; Bassendine MF; Grebely J
    Liver Int; 2016 Dec; 36(12):1774-1782. PubMed ID: 27224844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers.
    Abe Y; Aly HH; Hiraga N; Imamura M; Wakita T; Shimotohno K; Chayama K; Hijikata M
    Gastroenterology; 2013 Sep; 145(3):658-67.e11. PubMed ID: 23684750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients.
    Nielsen SU; Bassendine MF; Burt AD; Martin C; Pumeechockchai W; Toms GL
    J Virol; 2006 Mar; 80(5):2418-28. PubMed ID: 16474148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysophosphatidylcholine acyltransferase 1 is downregulated by hepatitis C virus: impact on production of lipo-viro-particles.
    Beilstein F; Lemasson M; Pène V; Rainteau D; Demignot S; Rosenberg AR
    Gut; 2017 Dec; 66(12):2160-2169. PubMed ID: 27582510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus-Infected Cells and Liver to Identify Pathways Associated With Disease Development.
    Lupberger J; Croonenborghs T; Roca Suarez AA; Van Renne N; Jühling F; Oudot MA; Virzì A; Bandiera S; Jamey C; Meszaros G; Brumaru D; Mukherji A; Durand SC; Heydmann L; Verrier ER; El Saghire H; Hamdane N; Bartenschlager R; Fereshetian S; Ramberger E; Sinha R; Nabian M; Everaert C; Jovanovic M; Mertins P; Carr SA; Chayama K; Dali-Youcef N; Ricci R; Bardeesy NM; Fujiwara N; Gevaert O; Zeisel MB; Hoshida Y; Pochet N; Baumert TF
    Gastroenterology; 2019 Aug; 157(2):537-551.e9. PubMed ID: 30978357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus hijacks host lipid metabolism.
    Syed GH; Amako Y; Siddiqui A
    Trends Endocrinol Metab; 2010 Jan; 21(1):33-40. PubMed ID: 19854061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients.
    Scholtes C; Ramière C; Rainteau D; Perrin-Cocon L; Wolf C; Humbert L; Carreras M; Guironnet-Paquet A; Zoulim F; Bartenschlager R; Lotteau V; André P; Diaz O
    Hepatology; 2012 Jul; 56(1):39-48. PubMed ID: 22290760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism.
    Bridge SH; Sheridan DA; Felmlee DJ; Crossey MM; Fenwick FI; Lanyon CV; Dubuc G; Seidah NG; Davignon J; Thomas HC; Taylor-Robinson SD; Toms GL; Neely RD; Bassendine MF
    J Hepatol; 2015 Apr; 62(4):763-70. PubMed ID: 25463543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins.
    Diaz O; Delers F; Maynard M; Demignot S; Zoulim F; Chambaz J; Trépo C; Lotteau V; André P
    J Gen Virol; 2006 Oct; 87(Pt 10):2983-2991. PubMed ID: 16963757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.
    Sagnelli C; Merli M; Uberti-Foppa C; Hasson H; Grandone A; Cirillo G; Salpietro S; Minichini C; Starace M; Messina E; Morelli P; Miraglia Del Giudice E; Lazzarin A; Coppola N; Sagnelli E
    World J Gastroenterol; 2016 Oct; 22(38):8509-8518. PubMed ID: 27784963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein lipase liberates free fatty acids to inhibit HCV infection and prevent hepatic lipid accumulation.
    Sun HY; Lin CC; Tsai PJ; Tsai WJ; Lee JC; Tsao CW; Cheng PN; Wu IC; Chiu YC; Chang TT; Young KC
    Cell Microbiol; 2017 Apr; 19(4):. PubMed ID: 27665576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus particles and lipoprotein metabolism.
    André P; Perlemuter G; Budkowska A; Bréchot C; Lotteau V
    Semin Liver Dis; 2005 Feb; 25(1):93-104. PubMed ID: 15732001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway.
    Murai K; Hikita H; Kai Y; Kondo Y; Fukuoka M; Fukutomi K; Doi A; Yamai T; Nakabori T; Fukuda R; Takahashi T; Miyakawa K; Suemizu H; Ryo A; Yamada R; Kodama T; Sakamori R; Tatsumi T; Takehara T
    Sci Rep; 2020 Jan; 10(1):941. PubMed ID: 31969598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
    Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
    Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.